Article abstract


Nature Biotechnology 26, 326 - 334 (2008)
Published online: 24 February 2008 | doi:10.1038/nbt1390

Engineered lentivector targeting of dendritic cells for in vivo immunization

Lili Yang1,3, Haiguang Yang2,3, Kendra Rideout2, Taehoon Cho2, Kye il Joo2, Leslie Ziegler2, Abigail Elliot1, Anthony Walls1, Dongzi Yu1, David Baltimore1 & Pin Wang2


We report a method of inducing antigen production in dendritic cells by in vivo targeting with lentiviral vectors that specifically bind to the dendritic cell–surface protein DC-SIGN. To target dendritic cells, we enveloped the lentivector with a viral glycoprotein from Sindbis virus engineered to be DC-SIGN–specific. In vitro, this lentivector specifically transduced dendritic cells and induced dendritic cell maturation. A high frequency (up to 12%) of ovalbumin (OVA)-specific CD8+ T cells and a significant antibody response were observed 2 weeks after injection of a targeted lentiviral vector encoding an OVA transgene into naive mice. This approach also protected against the growth of OVA-expressing E.G7 tumors and induced regression of established tumors. Thus, lentiviral vectors targeting dendritic cells provide a simple method of producing effective immunity and may provide an alternative route for immunization with protein antigens.

Top
  1. Division of Biology, California Institute of Technology, 1200 E. California Blvd, Pasadena, California 91125, USA.
  2. Mork Family Department of Chemical Engineering and Materials Science, University of Southern California, 925 Bloom Walk, HED-216, Los Angeles, California 90089, USA.
  3. These authors contributed equally to this work.

Correspondence to: David Baltimore1 e-mail: baltimo@caltech.edu

Correspondence to: Pin Wang2 e-mail: pinwang@usc.edu



MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.


Extra navigation

Open Innovation Challenges

naturejobs

ADVERTISEMENT